Asset Transfer and License AgreementAssignment and Assumption Agreement • March 13th, 2017 • Avenue Therapeutics, Inc. • Pharmaceutical preparations • New York
This Asset Transfer and License Agreement (the “Agreement”), is entered into as of February 17, 2015 (the “Effective Date”), by and between Revogenex Ireland Limited, an Irish limited company (“Revogenex”), and Coronado Biosciences, Inc., a Delaware corporation (“Coronado”). Coronado and Revogenex are both referred to herein as “Parties” or each individually, as a “Party.”
SECOND AMENDMENT TO CONSULTING AGREEMENTConsulting Agreement • March 13th, 2017 • Avenue Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS SECOND AMENDMENT TO CONSULTING AGREEMENT (this “Amendment”) is made as of this 2nd day of August, 2016 (the “Effective Date”) between Scott A. Reines, MD, PhD, having an address at 11 W Bridlewood Drive, New Hope, PA 18938 (“Consultant”), and Avenue Therapeutics, Inc., and its affiliates, having offices at 2 Gansevoort, 9th Floor, New York, NY 10014 (“Avenue”).
THIRD AMENDMENT TO CONSULTING AGREEMENTConsulting Agreement • March 13th, 2017 • Avenue Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS THIRD AMENDMENT TO CONSULTING AGREEMENT (this “Amendment”) is made on this 28th day of February 2017 with the amendment contained herein to be effective as of July 22, 2015 (the “Effective Date”) between Scott A. Reines, MD, PhD (“Consultant”) and Avenue Therapeutics, Inc., having offices at 2 Gansevoort, 9th Floor, New York, NY 10014 (“Avenue”).
Amendment 1 to Asset Transfer and License AgreementTransfer and License Agreement • March 13th, 2017 • Avenue Therapeutics, Inc. • Pharmaceutical preparations
This first amendment ("Amendment 1") to the Asset Transfer and License Agreement by and between Revogenex Ireland Limited, an Irish limited company ("Revogenex"), and Fortress Biotech, Inc. (f/k/a Coronado Biosciences, Inc.), a Delaware corporation ("Fortress")
